Loading clinical trials...
Loading clinical trials...
A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)
Conditions
Interventions
AZD6793
Placebo
Locations
363
United States
Research Site
Birmingham, Alabama, United States
Research Site
Glendale, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Canoga Park, California, United States
Start Date
June 27, 2025
Primary Completion Date
November 5, 2027
Completion Date
November 5, 2027
Last Updated
March 17, 2026
NCT07307781
NCT07509606
NCT07451977
NCT07477600
NCT07382258
NCT07052396
AstraZeneca Clinical Study Information Center
CONTACT
1-877-240-9479information.center@astrazeneca.comLead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions